{"id":19692,"date":"2026-04-13T19:46:10","date_gmt":"2026-04-13T19:46:10","guid":{"rendered":"https:\/\/ceronova.com\/?p=19692"},"modified":"2026-06-20T21:00:40","modified_gmt":"2026-06-20T21:00:40","slug":"car-t-cell-therapy-eligibility","status":"publish","type":"post","link":"https:\/\/ceronova.com\/ar\/car-t-cell-therapy-eligibility\/","title":{"rendered":"\u0647\u0644 \u0623\u0646\u0627 \u0645\u0631\u0634\u062d \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062a\u0627\u0626\u064a\u0629\u061f \u0641\u0647\u0645 \u0645\u0639\u0627\u064a\u064a\u0631 \u0623\u0647\u0644\u064a\u0629 \u0627\u0644\u0645\u0631\u064a\u0636"},"content":{"rendered":"<p id=\"p-rc_1960b0dec73edf7e-95\" data-path-to-node=\"15\"><span data-path-to-node=\"15,1\"><span class=\"citation-195\">When a cancer diagnosis is followed by the news that standard treatments are no longer working, it can feel like the end of the road<\/span><\/span><span data-path-to-node=\"15,3\">. <\/span><span data-path-to-node=\"15,5\"><span class=\"citation-194\">However, medical science has opened a new, revolutionary path: CAR-T cell therapy<\/span><\/span><span data-path-to-node=\"15,7\">. <\/span><span data-path-to-node=\"15,9\"><span class=\"citation-193\">This groundbreaking immunotherapy reprograms your own immune system to seek out and destroy cancer cells<\/span><\/span><span data-path-to-node=\"15,11\">.<\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-96\" data-path-to-node=\"16\"><span data-path-to-node=\"16,1\"><span class=\"citation-192\">But a common question arises: CAR-T cell therapy eligibility For me ?<\/span><\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-97\" data-path-to-node=\"17\"><span data-path-to-node=\"17,1\"><span class=\"citation-191\">At CeroNova, we understand that navigating treatment options from the Middle East and Africa (MEA) can be overwhelming<\/span><\/span><span data-path-to-node=\"17,3\">. <\/span><span data-path-to-node=\"17,5\"><span class=\"citation-190\">This comprehensive guide, based on guidelines from accredited medical institutions like the FDA, National Cancer Institute (NCI), and leading cancer centers, will help you understand the specific criteria\u2014including age, health status, and cancer type\u2014that determine if you or your loved one are a candidate for CAR-T cell therapy<\/span><\/span><span data-path-to-node=\"17,7\">.<\/span><\/p>\n<h2 data-path-to-node=\"18\">\u00a0The Core Criteria: What Makes a Patient Eligible?<\/h2>\n<p id=\"p-rc_1960b0dec73edf7e-98\" data-path-to-node=\"19\"><span data-path-to-node=\"19,0\">Determining eligibility for CAR-T cell therapy is a highly personalized process. <\/span><span data-path-to-node=\"19,2\"><span class=\"citation-189\">It is not a one-size-fits-all treatment<\/span><\/span><span data-path-to-node=\"19,4\">. <\/span><span data-path-to-node=\"19,6\"><span class=\"citation-188\">Instead, oncologists look at a combination of factors to ensure the therapy will be both safe and effective for you<\/span><\/span><span data-path-to-node=\"19,8\">.<\/span><\/p>\n<div style=\"text-align: center; margin: 30px 0;\">\n<p><img fetchpriority=\"high\" decoding=\"async\" style=\"max-width: 100%; height: auto;\" src=\"https:\/\/ceronova.com\/wp-content\/uploads\/2026\/04\/WhatsApp-Image-2026-04-13-at-10.53.33-PM.jpeg\" alt=\"\u0627\u0644\u062e\u0637\u0648\u0627\u062a \u0627\u0644\u062e\u0645\u0633 \u0644\u062a\u0642\u0646\u064a\u0629 \u0639\u0644\u0627\u062c \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062a\u0627\u0626\u064a\u0629 CAR-T \u0644\u0645\u062d\u0627\u0631\u0628\u0629 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u062f\u0645\" width=\"525\" height=\"292\" \/><\/p>\n<\/div>\n<h3 data-path-to-node=\"21\">\u00a01. The Right Diagnosis: Approved Cancer Types<\/h3>\n<p id=\"p-rc_1960b0dec73edf7e-99\" data-path-to-node=\"22\"><span data-path-to-node=\"22,1\"><span class=\"citation-187\">Currently, CAR-T cell therapy is FDA-approved specifically for certain types of blood cancers (hematologic malignancies)<\/span><\/span><span data-path-to-node=\"22,3\">. <\/span><span data-path-to-node=\"22,5\"><span class=\"citation-186\">It is not yet approved for solid tumors (like breast or lung cancer), though clinical trials are actively exploring these areas<\/span><\/span><span data-path-to-node=\"22,7\">.<\/span><\/p>\n<p data-path-to-node=\"23\">You may be eligible if you have been diagnosed with specific forms of:<\/p>\n<ul data-path-to-node=\"24\">\n<li>\n<p id=\"p-rc_1960b0dec73edf7e-100\" data-path-to-node=\"24,0,1\"><span data-path-to-node=\"24,0,1,0\"><b data-path-to-node=\"24,0,1,0\" data-index-in-node=\"0\"><span class=\"citation-185\">Leukemia:<\/span><\/b><span class=\"citation-185\"> Such as B-cell Acute Lymphoblastic Leukemia (ALL)<\/span><\/span><span data-path-to-node=\"24,0,1,2\">.<\/span><\/p>\n<\/li>\n<li>\n<p id=\"p-rc_1960b0dec73edf7e-101\" data-path-to-node=\"24,1,1\"><span data-path-to-node=\"24,1,1,0\"><b data-path-to-node=\"24,1,1,0\" data-index-in-node=\"0\"><span class=\"citation-184\">Lymphoma:<\/span><\/b><span class=\"citation-184\"> Including Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, and Marginal Zone Lymphoma<\/span><\/span><span data-path-to-node=\"24,1,1,2\">.<\/span><\/p>\n<\/li>\n<li>\n<p id=\"p-rc_1960b0dec73edf7e-102\" data-path-to-node=\"24,2,1\"><span data-path-to-node=\"24,2,1,0\"><b data-path-to-node=\"24,2,1,0\" data-index-in-node=\"0\"><span class=\"citation-183\">Multiple Myeloma:<\/span><\/b><span class=\"citation-183\"> A cancer of plasma cells in the bone marrow<\/span><\/span><span data-path-to-node=\"24,2,1,2\">.<\/span><\/p>\n<\/li>\n<\/ul>\n<h3 data-path-to-node=\"25\">(H3) 2. Relapsed or Refractory Disease<\/h3>\n<p id=\"p-rc_1960b0dec73edf7e-103\" data-path-to-node=\"26\"><span data-path-to-node=\"26,1\"><span class=\"citation-182\">CAR-T cell therapy is generally not a first-line treatment<\/span><\/span><span data-path-to-node=\"26,3\">. <\/span><span data-path-to-node=\"26,5\"><span class=\"citation-181\">It is designed for patients whose cancer is relapsed (came back after treatment) or refractory (did not respond to standard treatments)<\/span><\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-104\" data-path-to-node=\"27\"><span data-path-to-node=\"27,1\"><span class=\"citation-180\">For most FDA-approved CAR-T therapies, patients must have already tried at least one or two prior lines of systemic therapy (such as chemotherapy or targeted drugs) before becoming eligible<\/span><\/span><span data-path-to-node=\"27,3\">.<\/span><\/p>\n<h3 data-path-to-node=\"28\">\u00a03. Overall Health and Organ Function<\/h3>\n<p id=\"p-rc_1960b0dec73edf7e-105\" data-path-to-node=\"29\"><span data-path-to-node=\"29,1\"><span class=\"citation-179\">Because CAR-T cell therapy can cause significant side effects\u2014such as Cytokine Release Syndrome (CRS) and neurological toxicities\u2014your body must be strong enough to handle the treatment process<\/span><\/span><span data-path-to-node=\"29,3\">.<\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-106\" data-path-to-node=\"30\"><span data-path-to-node=\"30,1\"><span class=\"citation-178\">Oncologists will thoroughly evaluate your<\/span><\/span><span data-path-to-node=\"30,3\">:<\/span><\/p>\n<p>&nbsp;<\/p>\n<ul data-path-to-node=\"31\">\n<li>\n<p id=\"p-rc_1960b0dec73edf7e-107\" data-path-to-node=\"31,0,1\"><span data-path-to-node=\"31,0,1,0\"><b data-path-to-node=\"31,0,1,0\" data-index-in-node=\"0\"><span class=\"citation-177\">Cardiac (Heart) Function:<\/span><\/b><span class=\"citation-177\"> Ensuring your heart can withstand potential stress<\/span><\/span><span data-path-to-node=\"31,0,1,2\">.<\/span><\/p>\n<\/li>\n<li>\n<p id=\"p-rc_1960b0dec73edf7e-108\" data-path-to-node=\"31,1,1\"><span data-path-to-node=\"31,1,1,0\"><b data-path-to-node=\"31,1,1,0\" data-index-in-node=\"0\"><span class=\"citation-176\">Pulmonary (Lung) Function:<\/span><\/b><span class=\"citation-176\"> Checking for adequate oxygen exchange<\/span><\/span><span data-path-to-node=\"31,1,1,2\">.<\/span><\/p>\n<div class=\"source-inline-chip-container ng-star-inserted\"><\/div>\n<\/li>\n<li>\n<p id=\"p-rc_1960b0dec73edf7e-109\" data-path-to-node=\"31,2,1\"><span data-path-to-node=\"31,2,1,0\"><b data-path-to-node=\"31,2,1,0\" data-index-in-node=\"0\"><span class=\"citation-175\">Hepatic (Liver) and Renal (Kidney) Function:<\/span><\/b><span class=\"citation-175\"> Ensuring your body can process medications and clear toxins<\/span><\/span><span data-path-to-node=\"31,2,1,2\">.<\/span><\/p>\n<div class=\"source-inline-chip-container ng-star-inserted\"><\/div>\n<\/li>\n<li>\n<p id=\"p-rc_1960b0dec73edf7e-110\" data-path-to-node=\"31,3,1\"><span data-path-to-node=\"31,3,1,0\"><b data-path-to-node=\"31,3,1,0\" data-index-in-node=\"0\"><span class=\"citation-174\">Performance Status:<\/span><\/b><span class=\"citation-174\"> A measure of your ability to perform daily activities and your overall physical fitness<\/span><\/span><span data-path-to-node=\"31,3,1,2\">.<\/span><\/p>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"32\">\u00a0Debunking the Age Myth: Am I Too Old for CAR-T?<\/h2>\n<p id=\"p-rc_1960b0dec73edf7e-111\" data-path-to-node=\"33\"><span data-path-to-node=\"33,1\"><span class=\"citation-173\">One of the most persistent myths surrounding CAR-T cell therapy is that it is only for young people<\/span><\/span><span data-path-to-node=\"33,3\">. <\/span><span data-path-to-node=\"33,5\"><span class=\"citation-172\">This is entirely false<\/span><\/span><\/p>\n<div style=\"text-align: center; margin: 30px 0;\">\n<p><img decoding=\"async\" style=\"max-width: 100%; height: auto;\" src=\"https:\/\/ceronova.com\/wp-content\/uploads\/2026\/04\/WhatsApp-Image-2026-04-13-at-10.53.34-PM.jpeg\" alt=\"\u0627\u0644\u062e\u0637\u0648\u0627\u062a \u0627\u0644\u062e\u0645\u0633 \u0644\u062a\u0642\u0646\u064a\u0629 \u0639\u0644\u0627\u062c \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062a\u0627\u0626\u064a\u0629 CAR-T \u0644\u0645\u062d\u0627\u0631\u0628\u0629 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u062f\u0645\" width=\"525\" height=\"292\" \/><\/p>\n<\/div>\n<p><span data-path-to-node=\"33,7\">.<\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-112\" data-path-to-node=\"35\"><span data-path-to-node=\"35,1\"><span class=\"citation-171\">While one specific therapy (Kymriah for ALL) is approved for patients up to age 25, all other FDA-approved CAR-T therapies are specifically indicated for adults, with no upper age limit specified<\/span><\/span><span data-path-to-node=\"35,3\">.<\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-113\" data-path-to-node=\"36\"><span data-path-to-node=\"36,1\"><span class=\"citation-170\">Leading experts emphasize that health status, not age, should determine eligibility<\/span><\/span><span data-path-to-node=\"36,3\">. <\/span><span data-path-to-node=\"36,5\"><span class=\"citation-169\">According to specialists at Moffitt Cancer Center, an elderly patient in their 70s with well-managed conditions like hypertension may be an excellent candidate, whereas a younger patient whose organs have been severely damaged by previous treatments might not be<\/span><\/span><span data-path-to-node=\"36,7\">.<\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-114\" data-path-to-node=\"37,1\"><span data-path-to-node=\"37,1,0\"><i data-path-to-node=\"37,1,0\" data-index-in-node=\"0\"><span class=\"citation-168\">&#8220;Older patients can safely be treated with CAR T-cell therapy with careful planning and evaluation of comorbidities. Age alone is not a barrier.&#8221;<\/span><\/i><span class=\"citation-168\"> \u2014 Dr. Frederick Locke, Moffitt Cancer Center. <\/span><\/span><\/p>\n<h2 data-path-to-node=\"38\">\u00a0Overview of FDA-Approved CAR-T Therapies<\/h2>\n<p id=\"p-rc_1960b0dec73edf7e-115\" data-path-to-node=\"39\"><span data-path-to-node=\"39,1\"><span class=\"citation-167\">There are currently six FDA-approved CAR-T cell therapies, each tailored to specific types of blood cancer and specific patient profiles<\/span><\/span><span data-path-to-node=\"39,3\">.<\/span><\/p>\n<div style=\"text-align: center; margin: 30px 0;\">\n<p><img decoding=\"async\" style=\"max-width: 100%; height: auto;\" src=\"https:\/\/ceronova.com\/wp-content\/uploads\/2026\/04\/WhatsApp-Image-2026-04-13-at-10.53.34-PM-1.jpeg\" alt=\"\u0627\u0644\u062e\u0637\u0648\u0627\u062a \u0627\u0644\u062e\u0645\u0633 \u0644\u062a\u0642\u0646\u064a\u0629 \u0639\u0644\u0627\u062c \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062a\u0627\u0626\u064a\u0629 CAR-T \u0644\u0645\u062d\u0627\u0631\u0628\u0629 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u062f\u0645\" width=\"525\" height=\"292\" \/><\/p>\n<\/div>\n<div style=\"overflow-x: auto;\">\n<table style=\"width: 100%; border-collapse: collapse; margin: 20px 0; border: 1px solid #ddd; min-width: 600px;\">\n<thead>\n<tr style=\"background-color: #2c3e50; color: white;\">\n<th style=\"padding: 12px; border: 1px solid #ddd;\">Therapy Name<\/th>\n<th style=\"padding: 12px; border: 1px solid #ddd;\">Approved Indications<\/th>\n<th style=\"padding: 12px; border: 1px solid #ddd;\">Key Eligibility Note<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #ddd;\"><strong>KYMRIAH\u00ae (tisagenlecleucel)<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">ALL, Large B-cell Lymphoma, Follicular Lymphoma<\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">ALL approval is for patients up to age 25; others are for adults after 2+ prior lines.<\/td>\n<\/tr>\n<tr style=\"background-color: #f9f9f9;\">\n<td style=\"padding: 12px; border: 1px solid #ddd;\"><strong>YESCARTA\u00ae (axicabtagene ciloleucel)<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">Large B-cell Lymphoma, Follicular Lymphoma<\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">Approved for adults; can be used if refractory to first-line chemoimmunotherapy.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #ddd;\"><strong>TECARTUS\u00ae (brexucabtagene autoleucel)<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">Mantle Cell Lymphoma, ALL<\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">Approved for adult patients with relapsed\/refractory disease.<\/td>\n<\/tr>\n<tr style=\"background-color: #f9f9f9;\">\n<td style=\"padding: 12px; border: 1px solid #ddd;\"><strong>BREYANZI\u00ae (lisocabtagene maraleucel)<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">Large B-cell Lymphoma, CLL\/SLL, Follicular Lymphoma, Mantle Cell Lymphoma<\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">Broadest range of lymphoma approvals for adults after prior therapies.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 12px; border: 1px solid #ddd;\"><strong>ABECMA\u00ae (idecabtagene vicleucel)<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">Multiple Myeloma<\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">For adults after 2 or more prior lines of specific therapies.<\/td>\n<\/tr>\n<tr style=\"background-color: #f9f9f9;\">\n<td style=\"padding: 12px; border: 1px solid #ddd;\"><strong>CARVYKTI\u2122 (ciltacabtagene autoleucel)<\/strong><\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">Multiple Myeloma<\/td>\n<td style=\"padding: 12px; border: 1px solid #ddd;\">For adults after at least 1 prior line of specific therapy.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 data-path-to-node=\"42\">The Patient Journey: What to Expect<\/h2>\n<p id=\"p-rc_1960b0dec73edf7e-122\" data-path-to-node=\"43\"><span data-path-to-node=\"43,1\"><span class=\"citation-160\">If you meet the eligibility criteria, the CAR-T cell therapy journey involves several critical steps, requiring commitment and a strong support system<\/span><\/span><span data-path-to-node=\"43,3\">.<\/span><\/p>\n<div style=\"text-align: center; margin: 30px 0;\">\n<p><img loading=\"lazy\" decoding=\"async\" style=\"max-width: 100%; height: auto;\" src=\"https:\/\/ceronova.com\/wp-content\/uploads\/2026\/04\/WhatsApp-Image-2026-04-13-at-10.53.34-PM-2.jpeg\" alt=\"\u0627\u0644\u062e\u0637\u0648\u0627\u062a \u0627\u0644\u062e\u0645\u0633 \u0644\u062a\u0642\u0646\u064a\u0629 \u0639\u0644\u0627\u062c \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062a\u0627\u0626\u064a\u0629 CAR-T \u0644\u0645\u062d\u0627\u0631\u0628\u0629 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u062f\u0645\" width=\"525\" height=\"292\" \/><\/p>\n<\/div>\n<p id=\"p-rc_1960b0dec73edf7e-123\" data-path-to-node=\"45\"><span data-path-to-node=\"45,0\">A crucial logistical requirement for eligibility is availability. <\/span><span data-path-to-node=\"45,2\"><span class=\"citation-159\">Because of the risk of severe side effects, the FDA requires patients to stay within close proximity (usually a short drive) of the specialized treatment center for at least 30 days following the cell infusion<\/span><\/span><span data-path-to-node=\"45,4\">. <\/span><span data-path-to-node=\"45,6\"><span class=\"citation-158\">You will also need a dedicated caregiver available 24\/7 during this recovery period<\/span><\/span><span data-path-to-node=\"45,8\">.<\/span><\/p>\n<h2 data-path-to-node=\"46\">\u00a0The CeroNova Advantage: Bridging the MEA Region to Global Excellence<\/h2>\n<p data-path-to-node=\"48\">While the clinical criteria are universal, the logistics and costs of accessing CAR-T cell therapy in the West can be prohibitive for patients in the MEA region. This is where CeroNova changes the narrative. Through our strong partnerships with Chinese companies, we aim to deliver the latest innovation and gene therapy technologies to the MEA region at affordable prices. China currently leads the world in the volume of CAR-T clinical trials, offering the exact same international standards of care with significantly faster admission times and reduced financial burden.<\/p>\n<h2 data-path-to-node=\"49\">\u00a0Taking the Next Step with CeroNova<\/h2>\n<p id=\"p-rc_1960b0dec73edf7e-124\" data-path-to-node=\"50\"><span data-path-to-node=\"50,1\"><span class=\"citation-157\">Understanding the conditions for successful CAR-T cell therapy is the first step toward accessing this life-saving treatment<\/span><\/span><span data-path-to-node=\"50,3\">. <\/span><span data-path-to-node=\"50,5\"><span class=\"citation-156\">If you have a relapsed or refractory blood cancer, do not assume you are ineligible based on age or previous treatment failures<\/span><\/span><span data-path-to-node=\"50,7\">.<\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-125\" data-path-to-node=\"51\"><span data-path-to-node=\"51,1\"><span class=\"citation-155\">At CeroNova, we specialize in connecting patients with world-class medical facilities that offer these advanced therapies<\/span><\/span><span data-path-to-node=\"51,3\">. Backed by our scientific office in Cairo and our distribution hub in the UAE, our clinical specialists guide you through the complex evaluation process. <\/span><span data-path-to-node=\"51,5\"><span class=\"citation-154\">We ensure your medical records are reviewed by top cellular therapy specialists who can accurately determine your candidacy<\/span><\/span><span data-path-to-node=\"51,7\">.<\/span><\/p>\n<p id=\"p-rc_1960b0dec73edf7e-126\" data-path-to-node=\"52\"><span data-path-to-node=\"52,0\">Don&#8217;t let uncertainty delay your care. <\/span><span data-path-to-node=\"52,2\"><span class=\"citation-153\">Contact CeroNova today for a comprehensive review of your case and discover if CAR-T cell therapy is the right path for you<\/span><\/span><span data-path-to-node=\"52,4\">.<\/span><\/p>\n<ul data-path-to-node=\"53\">\n<li>\n<p data-path-to-node=\"53,0,0\"><b data-path-to-node=\"53,0,0\" data-index-in-node=\"0\">Email:<\/b> CS@Ceronova.com<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"53,1,0\"><b data-path-to-node=\"53,1,0\" data-index-in-node=\"0\">Phone:<\/b> +971 585843897<\/p>\n<\/li>\n<\/ul>\n<hr data-path-to-node=\"54\" \/>\n<p data-path-to-node=\"55\"><b data-path-to-node=\"55\" data-index-in-node=\"0\">References<\/b><\/p>\n<div style=\"overflow-x: auto; margin: 20px 0;\">\n<ul style=\"padding-left: 20px; line-height: 1.6; word-break: break-word;\">\n<li style=\"margin-bottom: 12px;\"><strong>[1]<\/strong> National Cancer Institute. (2025, February 26).<br \/>\nCAR T Cells: Engineering Immune Cells to Treat Cancer.<br \/>\nRetrieved from<br \/>\n<a style=\"color: #3498db; text-decoration: underline;\" href=\"https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells\" target=\"_blank\" rel=\"noopener\"><br \/>\nhttps:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells<br \/>\n<\/a><\/li>\n<li style=\"margin-bottom: 12px;\"><strong>[2]<\/strong> Cleveland Clinic. (2024, February 14).<br \/>\nCAR T-Cell Therapy: What It Is &amp; How It Works.<br \/>\nRetrieved from<br \/>\n<a style=\"color: #3498db; text-decoration: underline;\" href=\"https:\/\/my.clevelandclinic.org\/health\/treatments\/17726-car-t-cell-therapy\" target=\"_blank\" rel=\"noopener\"><br \/>\nhttps:\/\/my.clevelandclinic.org\/health\/treatments\/17726-car-t-cell-therapy<br \/>\n<\/a><\/li>\n<li style=\"margin-bottom: 12px;\"><strong>[3]<\/strong> UPMC Hillman Cancer Center. (n.d.).<br \/>\nFDA-approved CAR T-cell Therapies.<br \/>\nRetrieved from<br \/>\n<a style=\"color: #3498db; text-decoration: underline;\" href=\"https:\/\/hillman.upmc.com\/mario-lemieux-center\/treatment\/car-t-cell-therapy\/fda-approved-therapies\" target=\"_blank\" rel=\"noopener\"><br \/>\nhttps:\/\/hillman.upmc.com\/mario-lemieux-center\/treatment\/car-t-cell-therapy\/fda-approved-therapies<br \/>\n<\/a><\/li>\n<li style=\"margin-bottom: 12px;\"><strong>[4]<\/strong> Moffitt Cancer Center. (2022, January 13).<br \/>\nHealth Status, not Age, Should Determine CAR T Eligibility.<br \/>\nRetrieved from<br \/>\n<a style=\"color: #3498db; text-decoration: underline;\" href=\"https:\/\/www.moffitt.org\/endeavor\/archive\/health-status-not-age-should-determine-car-t-eligibility\/\" target=\"_blank\" rel=\"noopener\"><br \/>\nhttps:\/\/www.moffitt.org\/endeavor\/archive\/health-status-not-age-should-determine-car-t-eligibility\/<br \/>\n<\/a><\/li>\n<\/ul>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>When a cancer diagnosis is followed by the news that standard treatments are no longer working, it can feel like the end of the road. However, medical science has opened a new, revolutionary path: CAR-T cell therapy. This groundbreaking immunotherapy reprograms your own immune system to seek out and destroy cancer cells. But a common [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":19694,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_joinchat":[],"footnotes":""},"categories":[23,135],"tags":[],"class_list":["post-19692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-treatment","category-treatment_en"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/posts\/19692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/comments?post=19692"}],"version-history":[{"count":8,"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/posts\/19692\/revisions"}],"predecessor-version":[{"id":19725,"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/posts\/19692\/revisions\/19725"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/media\/19694"}],"wp:attachment":[{"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/media?parent=19692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/categories?post=19692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ceronova.com\/ar\/wp-json\/wp\/v2\/tags?post=19692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}